Experience with extracoporeal elimination therapy in myasthenia gravis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F11%3A43874731" target="_blank" >RIV/60162694:G44__/11:43874731 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.transci.2011.10.003" target="_blank" >http://dx.doi.org/10.1016/j.transci.2011.10.003</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.transci.2011.10.003" target="_blank" >10.1016/j.transci.2011.10.003</a>

Result language
angličtina
Original language name
Experience with extracoporeal elimination therapy in myasthenia gravis
Original language description
We describe our experience with plasma exchange (PE) and immunoadsorption in patients with myasthenia gravis. The group of 27 patients consists of 21 patients treated with PE and 6 patients who received immunoadsorption. PE therapy led to stabilization in 20 patients. In patients treated with immunoadsorption, therapy could be discontinued in 2 patients after 13 months of therapy, and the other 4 patients were stabilized without myasthenic crises after 6-9 years of therapy. Extracorporeal elimination therapy through PE or immunoadsorption is effective and sometimes life saving and is safe in the hands of an experienced team (6% complication rate). (C) 2011 Elsevier Ltd. All rights reserved.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)